BOOK
Transfusion Medicine, An Issue of Hematology/Oncology Clinics of North America, E-Book
Jeanne E. Hendrickson | Christopher A. Tormey
(2016)
Additional Information
Book Details
Abstract
Blood transfusions are an important part of hematologic care. This issue of Hematology/Oncology Clinics will focus on transfusion medicine and will include articles on: RBC Transfusions: Conclusions from Clinical Trials and the Establishment of Evidence-based Guidelines for Adults, Platelet Transfusions: Conclusions from Clinical Trials and the Establishment of Evidence- and/or Experience-based Guidelines for Adults, Use and Overuse of Plasma Products: Establishment of Evidence- and/or Experience-based Guidelines for Plasma Transfusion in Adults, Stem Cell Mobilization/Collection: Coordination Between Hem/Onc, Transplant, and Transfusion Services, Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications, and many more exciting articles.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Transfusion Medicine\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Transfusion Medicine\r | vii | ||
| Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy\r | vii | ||
| Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia:\rConclusions from Clinical Trials and Current Controversies\r | vii | ||
| Assessing the Rationale and Effectiveness of Frozen Plasma Transfusions: An Evidence-based Review\r | vii | ||
| Autologous Stem Cell Mobilization and Collection\r | viii | ||
| Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications\r | viii | ||
| Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk\r | viii | ||
| Transfusion Reactions\r | viii | ||
| Red Blood Cell Antibodies in Hematology/Oncology Patients: Interpretation of\rImmunohematologic Tests and Clinical Significance of Detected Antibodies\r | ix | ||
| Modifications to Blood Components: When to Use them and What is the Evidence?\r | ix | ||
| Management of the Platelet Refractory Patient\r | ix | ||
| Management of Thrombotic Microangiopathic Hemolytic Anemias with\rTherapeutic Plasma Exchange: When It Works and When It Does Not\r | x | ||
| Transfusion Considerations in Pediatric Hematology and Oncology Patients\r | x | ||
| HEMATOLOGY/ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| August 2016 | xi | ||
| October 2016 | xi | ||
| December 2016 | xi | ||
| RECENT ISSUES | xi | ||
| April 2016 | xi | ||
| February 2016 | xi | ||
| December 2015 | xi | ||
| Preface: Transfusion Medicine\r | xiii | ||
| Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy | 529 | ||
| Key points | 529 | ||
| INTRODUCTION | 529 | ||
| GOALS AND RISKS OF RED BLOOD CELL TRANSFUSION | 530 | ||
| RISKS FROM ANEMIA | 531 | ||
| CLINICAL TRIALS | 531 | ||
| Intensive Care Unit and Sepsis | 532 | ||
| Bleeding | 532 | ||
| Postoperative Patients | 533 | ||
| Cardiovascular Events | 534 | ||
| TRANSFUSION ALTERNATIVES: ERYTHROPOIESIS-STIMULATING AGENTS | 535 | ||
| CLINICAL GUIDELINES | 536 | ||
| FUTURE STUDIES | 537 | ||
| SUMMARY | 537 | ||
| REFERENCES | 537 | ||
| Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia | 541 | ||
| Key points | 541 | ||
| INTRODUCTION | 542 | ||
| METHODS | 542 | ||
| MAIN FINDINGS FOR REVIEW | 542 | ||
| RECENT TRIALS | 543 | ||
| DISEASE AND TREATMENT CATEGORY | 543 | ||
| PLATELET DOSE | 552 | ||
| PLATELET TRANSFUSION THRESHOLD | 552 | ||
| LIMITATIONS IN THE INTERPRETATION OF PLATELET TRANSFUSION TRIALS | 553 | ||
| RISK FACTORS FOR BLEEDING ASIDE FROM PLATELET COUNT | 554 | ||
| HEMATOLOGIC DISEASE LINKED WITH BLEEDING | 555 | ||
| ANTIFIBRINOLYTICS | 556 | ||
| SUMMARY | 556 | ||
| REFERENCES | 557 | ||
| Assessing the Rationale and Effectiveness of Frozen Plasma Transfusions | 561 | ||
| Key points | 561 | ||
| FROZEN PLASMA PRODUCTS | 562 | ||
| RATIONALE FOR FROZEN PLASMA USE | 562 | ||
| INDICATIONS FOR FROZEN PLASMA TRANSFUSIONS | 564 | ||
| Prophylactic Frozen Plasma Transfusions for Nonbleeding Patients, and Before Invasive Procedures | 564 | ||
| Cardiac Surgery | 565 | ||
| Liver Disease | 565 | ||
| Warfarin Reversal | 566 | ||
| Trauma/Massive Bleeding | 567 | ||
| Thrombotic Thrombocytopenic Purpura | 567 | ||
| DOSE OF FROZEN PLASMA | 567 | ||
| SUMMARY | 568 | ||
| REFERENCES | 568 | ||
| Autologous Stem Cell Mobilization and Collection | 573 | ||
| Key points | 573 | ||
| INTRODUCTION | 573 | ||
| DISCOVERY OF THE HEMATOPOIETIC STEM CELL NICHE AND CLINICAL TRANSLATION | 574 | ||
| CLINICAL HEMATOPOIETIC STEM/PROGENITOR CELL MOBILIZATION | 574 | ||
| Chemotherapy Mobilization | 574 | ||
| Colony-Stimulating Factors | 575 | ||
| Granulocyte-colony stimulating factor (filgrastim) | 576 | ||
| Modified filgrastim | 576 | ||
| Biosimilar granulocyte-colony stimulating factor | 577 | ||
| Granulocyte-macrophage colony-stimulating factor (sargramostim) | 577 | ||
| Small Molecule Chemokine Analogs and Monoclonal Antibodies | 578 | ||
| Plerixafor | 578 | ||
| Stem cell factor (ancestim) | 578 | ||
| Recombinant very late antigen-4 (VLA-4) antagonist | 579 | ||
| CLINICAL APPROACHES IN COLLECTING MOBILIZED HEMATOPOIETIC STEM/PROGENITOR CELLS | 579 | ||
| Predicting Successful Collection | 579 | ||
| White blood cells | 579 | ||
| Peripheral blood CD34 count | 580 | ||
| Hematopoietic progenitor cell count | 581 | ||
| Donor-specific factors | 581 | ||
| Increased Collection Efficiency with On-Demand or Preemptive Plerixafor | 581 | ||
| Optimized Leukapheresis Procedures | 582 | ||
| Large volume leukapheresis | 582 | ||
| Peripheral blood collection platforms | 582 | ||
| LOGISTICAL CONSIDERATIONS DURING STEM CELL COLLECTION | 583 | ||
| Prerequisites to Receiving Leukapheresis | 583 | ||
| Venous line placement | 583 | ||
| Preprocedural hematocrit and platelet counts | 583 | ||
| Adverse Events and Complications of Apheresis | 583 | ||
| SUMMARY | 584 | ||
| REFERENCES | 584 | ||
| Management of Patients with Sickle Cell Disease Using Transfusion Therapy | 591 | ||
| Key points | 591 | ||
| INTRODUCTION | 591 | ||
| METHODS OF TRANSFUSION THERAPY | 592 | ||
| INDICATIONS | 593 | ||
| Acute Splenic Sequestration | 593 | ||
| Transient Aplastic Crisis | 593 | ||
| Acute Chest Syndrome | 594 | ||
| Acute Sickle Hepatopathy | 594 | ||
| Multisystem Organ Failure | 595 | ||
| Preoperative Transfusion Management | 595 | ||
| Neurologic Complications | 595 | ||
| CONTROVERSIAL INDICATIONS | 597 | ||
| Pulmonary Hypertension | 597 | ||
| Pregnancy in Sickle Cell Disease | 597 | ||
| Leg Ulcers | 598 | ||
| Vasoocclusive Crisis | 598 | ||
| Priapism | 599 | ||
| PREVENTION OF COMPLICATIONS | 599 | ||
| Alloimmunization | 599 | ||
| Monitoring and Treatment of Iron Overload | 602 | ||
| SUMMARY | 603 | ||
| REFERENCES | 603 | ||
| Pathogen Inactivation Technologies | 609 | ||
| Key points | 609 | ||
| SAFETY OF BLOOD PRODUCTS | 609 | ||
| CURRENT STATUS OF PATHOGEN INACTIVATION TECHNOLOGIES | 610 | ||
| Pathogen Inactivation Technologies for Plasma | 611 | ||
| Solvent/detergent method | 611 | ||
| Methylene blue | 611 | ||
| Amotosalen/UV and riboflavin/UV | 611 | ||
| Pathogen Inactivation Technologies for Red Blood Cells | 612 | ||
| Pathogen Inactivation Technologies for Platelets | 612 | ||
| Pathogen Inactivation Technologies for Whole Blood | 613 | ||
| EFFECT OF PATHOGEN INACTIVATION TECHNOLOGIES ON PATHOGENS | 613 | ||
| EFFECT OF PATHOGEN INACTIVATION TECHNOLOGIES ON THE QUALITY OF BLOOD PRODUCTS | 613 | ||
| FUTURE DIRECTIONS | 614 | ||
| REFERENCES | 615 | ||
| Transfusion Reactions | 619 | ||
| Key points | 619 | ||
| HEMOLYTIC TRANSFUSION REACTIONS | 619 | ||
| DELAYED HEMOLYTIC REACTIONS | 622 | ||
| FEBRILE NONHEMOLYTIC TRANSFUSION REACTIONS | 623 | ||
| ALLERGIC TRANSFUSION REACTIONS | 624 | ||
| HYPOTENSIVE TRANSFUSION REACTION | 625 | ||
| INFECTIOUS COMPLICATIONS OF TRANSFUSION | 625 | ||
| TRANSFUSION-RELATED ACUTE LUNG INJURY | 627 | ||
| TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD | 627 | ||
| TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE | 628 | ||
| POSTTRANSFUSION PURPURA | 629 | ||
| AIR EMBOLI | 629 | ||
| NATIONAL HEALTHCARE SAFETY NETWORK | 629 | ||
| SUMMARY | 630 | ||
| REFERENCES | 630 | ||
| Red Blood Cell Antibodies in Hematology/Oncology Patients | 635 | ||
| Key points | 635 | ||
| INTRODUCTION | 635 | ||
| BASIC TESTS OF COMPATIBILITY IN THE BLOOD BANK | 636 | ||
| Principle of Hemagglutination and Testing Platforms in the Blood Bank | 636 | ||
| ABO and Rh(D) Blood Group Phenotyping | 636 | ||
| COMPLEX TESTS OF COMPATIBILITY AND/OR ANTIBODY IDENTIFICATION IN THE BLOOD BANK | 637 | ||
| Indirect Antiglobulin Test | 637 | ||
| Identification of Red Blood Cell Antibodies by Panel Testing | 637 | ||
| Direct Antiglobulin Test | 637 | ||
| Red Blood Cell Elution | 641 | ||
| Cold Autoantibody Screen, Thermal Amplitude, and Titers | 641 | ||
| Donath-Landsteiner Test | 643 | ||
| Summary for Complex Tests of Compatibility and/or Antibody Identification | 643 | ||
| RED BLOOD CELL ALLOIMMUNIZATION IN HEMATOLOGY/ONCOLOGY DISORDERS AND ITS CLINICAL SIGNIFICANCE | 643 | ||
| Alloimmunization in Hematologic or Oncologic Disorders (Nonhemoglobinopathies) | 643 | ||
| Myelodysplastic syndromes, acute myeloid leukemia, and aplastic anemia | 643 | ||
| Acute lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma | 644 | ||
| Bone marrow/hematopoietic progenitor cell transplant | 644 | ||
| Solid tumors and general patients with cancer | 644 | ||
| Alloimmunization in Hemoglobinopathies | 645 | ||
| Sickle cell disease | 645 | ||
| Thalassemia | 646 | ||
| RED BLOOD CELL ALLOANTIBODY MITIGATION STRATEGIES | 646 | ||
| SUMMARY | 647 | ||
| REFERENCES | 648 | ||
| Modifications to Blood Components | 653 | ||
| Key points | 653 | ||
| TOPIC OVERVIEW INTRODUCTION | 653 | ||
| LEUKOREDUCTION | 653 | ||
| Leukoreduction Summary | 655 | ||
| Benefits | 655 | ||
| Drawbacks | 655 | ||
| IRRADIATION | 655 | ||
| Irradiation Summary | 657 | ||
| Benefits | 657 | ||
| Drawbacks | 657 | ||
| VOLUME REDUCTION | 658 | ||
| Volume Reduction Summary | 658 | ||
| Benefits | 658 | ||
| Drawbacks | 658 | ||
| SPLITTING | 658 | ||
| Splitting Summary | 659 | ||
| Benefits | 659 | ||
| Drawbacks | 659 | ||
| WASHING | 659 | ||
| Washing Summary | 660 | ||
| Benefits | 660 | ||
| Drawbacks | 660 | ||
| SUMMARY | 660 | ||
| REFERENCES | 660 | ||
| Management of the Platelet Refractory Patient | 665 | ||
| Key points | 665 | ||
| INTRODUCTION | 665 | ||
| DEFINITION OF PLATELET REFRACTORINESS | 666 | ||
| CAUSE | 667 | ||
| TRANSFUSION SERVICE FACTORS | 669 | ||
| INCIDENCE | 670 | ||
| LABORATORY DIAGNOSIS OF IMMUNE-MEDIATED PLATELET REFRACTORINESS | 670 | ||
| MANAGEMENT | 670 | ||
| HUMAN LEUKOCYTE ANTIGEN MATCHING | 670 | ||
| CROSSMATCHING | 671 | ||
| ANTIBODY SPECIFICITY PREDICTION | 674 | ||
| SUMMARY OF RECOMMENDATIONS | 674 | ||
| REFERENCES | 675 | ||
| Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange | 679 | ||
| Key points | 679 | ||
| INTRODUCTION | 680 | ||
| THROMBOTIC MICROANGIOPATHIES) | 680 | ||
| INFECTION-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA | 681 | ||
| Human immunodeficiency virus-associated Thrombotic Thrombocytopenic Purpura | 681 | ||
| INFECTION-ASSOCIATED HEMOLYTIC UREMIC SYNDROME | 684 | ||
| Typical Hemolytic Uremic Syndrome, Diarrhea-associated Hemolytic Uremic Syndrome, or Shiga Toxin–associated Hemolytic Uremi ... | 684 | ||
| Streptococcus pneumoniae–associated hemolytic uremic syndrome | 685 | ||
| Atypical Hemolytic Uremic Syndrome (Complement Regulatory Pathway-associated Hemolytic Uremic Syndrome or Complement-mediat ... | 686 | ||
| HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHIES | 686 | ||
| RENAL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHIES | 687 | ||
| MALIGNANCY-ASSOCIATED THROMBOTIC MICROANGIOPATHIES | 688 | ||
| DRUG-ASSOCIATED THROMBOTIC MICROANGIOPATHIES (DRUG-MEDIATED THROMBOTIC MICROANGIOPATHIES IMMUNE REACTION OR DRUG-MEDIATED T ... | 689 | ||
| SUMMARY | 691 | ||
| REFERENCES | 691 | ||
| Transfusion Considerations in Pediatric Hematology and Oncology Patients | 695 | ||
| Key points | 695 | ||
| INTRODUCTION | 696 | ||
| EPIDEMIOLOGY OF TRANSFUSIONS IN PEDIATRIC PATIENTS | 696 | ||
| RED BLOOD CELL TRANSFUSIONS | 696 | ||
| PLATELET TRANSFUSIONS | 700 | ||
| PLASMA TRANSFUSIONS | 701 | ||
| GRANULOCYTE TRANSFUSIONS | 702 | ||
| REFERENCES | 704 | ||
| Index | 711 |